Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma

Shevchenko,Valery; Arnotskaya,Nataliya; Korneyko,Maria; Zaytsev,Sergry; Khotimchenko,Yuriy; Sharma,Hary; Bryukhovetskiy,Igor

doi:10.3892/or.2019.7043

Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma

Authors:
- Valery Shevchenko
- Nataliya Arnotskaya
- Maria Korneyko
- Sergry Zaytsev
- Yuriy Khotimchenko
- Hary Sharma
- Igor Bryukhovetskiy
View Affiliations

Affiliations: School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russia, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115478, Russia, Department of Surgical Sciences, Anesthesiology and Intensive Care Medicine, University Hospital, Uppsala University, SE‑75185 Uppsala, Sweden
Published online on: March 5, 2019 https://doi.org/10.3892/or.2019.7043
Pages: 3080-3088

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive types of brain tumor and is highly resistant to therapy. The median survival time for patients with GBM is 15 months. GBM resistance to treatment is associated with cancer stem cells (CSCs). CD133 membrane glycoprotein is the best‑known marker of GBM CSCs. The Wnt signaling pathway plays an important role in the proliferation of all stem cells. To the best of our knowledge, the present study was the first to examine the expression levels of proteins associated with the Wnt signaling pathway in СD133+ CSCs of human GBM. Furthermore, potential targets that may regulate СD133+ CSCs in human GBM were investigated. The human GBM U‑87MG cell line was cultured in neurobasal medium supplemented with B27, fibroblast growth factor, epidermal growth factor and no serum. Immunohistochemical characteristics of glioma spheres were investigated based on the expression of key markers of CSCs. CD133+ cells were extracted from glioma spheres by cell sorting and then lysed. High‑performance liquid chromatography‑mass spectrometry was used for proteome analysis. Lysates of CD133‑ cells in GBM were used for comparison. The present study was the first to describe the conceptual proteome differences between GBM and CD133+ CSCs of the common pool. Major differences were identified in the glycolysis/gluconeogenesis, focal adhesion, tight junction and Wnt signaling pathways. This study aimed to analyze the crucial role that proteins of the Wnt signaling pathway play in stem cell proliferation. The identified proteins were analyzed for their association with the Wnt signaling pathway using the international open databases PubMed, Protein Analysis Through Evolutionary Relationships, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes and Search Tool for the Retrieval of Interacting Genes/Proteins. An increased expression of 12 proteins associated with the Wnt signaling pathway were identified in GBM CD133+ CSCs, which included catenin β‑1, disheveled associated activator of morphogenesis 1, RAC family small GTPase 2 and RAS homolog gene family member A, a number of which are also associated with adherens junctions. The Wnt signaling pathway is not upregulated in CSCs; however, the high expression levels of adenomatous polyposis coli, β‑catenin, C‑terminal binding protein (CtBP) and RuvB‑like AAA ATPase 1 (RUVBL1 or Pontin52) proteins suggest the possibility of alternative activation of specific genes in the nuclei of these cells. Calcyclin‑binding protein, casein kinase II α, casein kinase II β, CtBP1, CtBP2, CUL1 and RUVBL1 proteins may be used as targets for the pharmaceutical regulation of CSCs in complex GBM treatment.

View Figures

View References

1	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of Tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Brada M, van den Bent MJ, Tonn JC and Pentheroudakis G; ESMO Guidelines Working Group, : High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii93–iii101. 2014. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Rycaj K and Tang DG: Cancer stem cells and radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, Malouf D, Gillatt D and Li Y: Cancer stem cells and signaling pathways in radio-resistance. Oncotarget. 7:11002–11017. 2016.PubMed/NCBI
6	Friedmann-Morvinski D: Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog. 19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bryukhovetskiy I, Ponomarenko A, Lyakhova I, Zaitsev S, Zayats Y, Korneyko M, Eliseikina M, Mischenko P, Shevchenko V, Shanker Sharma H, et al: Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). Int J Mol Med. 42:691–702. 2018.PubMed/NCBI
8	Bradshaw A, Wickremesekera A, Brasch HD, Chibnall AM, Davis PF, Tan ST and Itinteang T: Cancer stem cells in glioblastoma multiforme. Front Surg. 3:482016. View Article : Google Scholar : PubMed/NCBI
9	Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, Kountouri N, Ng W, Morokoff AP and Mantamadiotis T: Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS One. 12:e01727912017. View Article : Google Scholar : PubMed/NCBI
10	Brown DV, Daniel PM, D'Abaco GM, Gogos A, Ng W, Morokoff AP and Mantamadiotis T: Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget. 6:6267–6280. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bryukhovetskiy A, Shevchenko V, Kovalev S, Chekhonin V, Baklaushev V, Bryukhovetskiy I and Zhukova M: To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans. Cell Transplant. 23 (Suppl 1):S151–S170. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tan SH and Barker N: Wnt signaling in adult epithelial stem cells and cancer. Prog Mol Biol Transl Sci. 153:21–79. 2018. View Article : Google Scholar : PubMed/NCBI
13	Kahn M: Wnt signaling in stem cells and cancer stem cells: A tale of two coactivators. Prog Mol Biol Transl Sci. 153:209–244. 2018. View Article : Google Scholar : PubMed/NCBI
14	Kretzschmar K and Clevers H: Wnt/β-catenin signaling in adult mammalian epithelial stem cells. Dev Biol. 428:273–282. 2017. View Article : Google Scholar : PubMed/NCBI
15	Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, Tang S, Liu H, Zhang F, Huang J, et al: Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 3:11–40. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kim Y, Kim KH, Lee J, Lee YA, Kim M, Lee SJ, Park K, Yang H, Jin J, Joo KM, et al: Wnt activation is implicated in glioblastoma radioresistance. Lab Invest. 92:466–473. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kahlert UD, Suwala AK, Koch K, Natsumeda M, Orr BA, Hayashi M, Maciaczyk J and Eberhart CG: Pharmacologic Wnt inhibition reduces proliferation, survival, and clonogenicity of glioblastoma cells. J Neuropathol Exp Neurol. 74:889–900. 2015. View Article : Google Scholar : PubMed/NCBI
18	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
19	Bryukhovetskiy I and Shevchenko V: Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells. Oncol Lett. 12:1581–1590. 2016. View Article : Google Scholar : PubMed/NCBI
20	Bryukhovetskiy IS, Dyuizen IV, Shevchenko VE, Bryukhovetskiy AS, Mischenko PV, Milkina EV and Khotimchenko YS: Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme. Mol Med Rep. 14:4511–4520. 2016. View Article : Google Scholar : PubMed/NCBI
21	Mizrak D1, Brittan M and Alison M: CD133: Molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
22	Shmelkov SV, St Clair R, Lyden D and Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhang LS and Lum L: Chemical modulation of WNT signaling in cancer. Prog Mol Biol Transl Sci. 153:245–269. 2018. View Article : Google Scholar : PubMed/NCBI
24	Gong A and Huang S: FoxM1 and Wnt/β-catenin signaling in glioma stem cells. Cancer Res. 72:5658–5662. 2012. View Article : Google Scholar : PubMed/NCBI
25	Nikuseva-Martić T, Beros V, Pećina-Slaus N, Pećina H and Bulić-Jakus F: Genetic changes of CDH1, APC, and CTNNB1 found in human brain tumors. Pathol Res Pract. 203:779–787. 2007. View Article : Google Scholar : PubMed/NCBI
26	Dipro S, Al-Otaibi F, Alzahrani A, Ulhaq A and Al Shail E: Turcot syndrome: A synchronous clinical presentation of glioblastoma multiforme and adenocarcinoma of the colon. Case Rep Oncol Med. 2012:7202732012.PubMed/NCBI
27	Shi H, Gao Y, Tang Y, Wu Y, Gong H, Du J, Zheng B, Hu J, Shi Q and Yu R: CacyBP/SIP protein is important for the proliferation of human glioma cells. IUBMB Life. 66:286–291. 2014. View Article : Google Scholar : PubMed/NCBI
28	Yan S, Li A and Liu Y: CacyBP/SIP inhibits the migration and invasion behaviors of glioblastoma cells through activating Siah1 mediated ubiquitination and degradation of cytoplasmic p27. Cell Biol Int. 42:216–226. 2018. View Article : Google Scholar : PubMed/NCBI
29	Tang Y, Zhan W, Cao T, Tang T, Gao Y, Qiu Z, Fu C, Qian F, Yu R and Shi H: CacyBP/SIP inhibits Doxourbicin-induced apoptosis of glioma cells due to activation of ERK1/2. IUBMB Life. 68:211–219. 2016. View Article : Google Scholar : PubMed/NCBI
30	Chen Y, Zhang K, Wang X, Li Q, Wu Q and Ning X: Cell cycle-dependent translocation and regulatory mechanism of CacyBP/SIP in gastric cancer cells. Anticancer Drugs. 29:19–28. 2018. View Article : Google Scholar : PubMed/NCBI
31	Nitta RT, Gholamin S, Feroze AH, Agarwal M, Cheshier SH, Mitra SS and Li G: Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway. Oncogene. 34:3688–3699. 2015. View Article : Google Scholar : PubMed/NCBI
32	Rowse AL, Gibson SA, Meares GP, Rajbhandari R, Nozell SE, Dees KJ, Hjelmeland AB, McFarland BC and Benveniste EN: Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells. J Neurooncol. 132:219–229. 2017. View Article : Google Scholar : PubMed/NCBI
33	Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C and Candiota AP: Targeting protein kinase CK2: Evaluating CX-4945 potential for GL261 glioblastoma therapy in immunocompetent mice. Pharmaceuticals. 10(pii): E242017. View Article : Google Scholar : PubMed/NCBI
34	Chikano Y, Domoto T, Furuta T, Sabit H, Kitano-Tamura A, Pyko IV, Takino T, Sai Y, Hayashi Y, Sato H, et al: Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway. Mol Cancer Ther. 14:564–574. 2015. View Article : Google Scholar : PubMed/NCBI
35	Zhao P, Li Q, Shi Z, Li C, Wang L, Liu X, Jiang C, Qian X, You Y, Liu N, et al: GSK-3β regulates tumor growth and angiogenesis in human glioma cells. Oncotarget. 6:31901–31915. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zhang Y, Wen YL, Ma JW, Ye JC, Wang X, Huang JX, Meng CY, Xu XZ, Wang SX and Zhong XY: Tetrandrine inhibits glioma stem-like cells by repressing β-catenin expression. Int J Oncol. 50:101–110. 2017. View Article : Google Scholar : PubMed/NCBI
37	Náger M, Santacana M, Bhardwaj D, Valls J, Ferrer I, Nogués P, Cantí C and Herreros J: Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion. Cell Cycle. 14:3644–3655. 2015. View Article : Google Scholar : PubMed/NCBI
38	Kahlert UD, Mooney SM, Natsumeda M, Steiger HJ and Maciaczyk J: Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways. Int J Cancer. 140:10–22. 2017. View Article : Google Scholar : PubMed/NCBI
39	Kierulf-Vieira KS, Sandberg CJ, Grieg Z, Günther CC, Langmoen IA and Vik-Mo EO: Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation. Exp Cell Res. 340:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
40	Buckley CD, Tan J, Anderson KL, Hanein D, Volkmann N, Weis WI, Nelson WJ and Dunn AR: Cell adhesion. The minimal cadherin-catenin complex binds to actin filaments under force. Science. 346:12542112014. View Article : Google Scholar : PubMed/NCBI
41	Ji H, Wang J, Fang B, Fang X and Lu Z: α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation. J Neurooncol. 103:445–451. 2011. View Article : Google Scholar : PubMed/NCBI
42	Xu M, Yang X, Zhao J, Zhang J, Zhang S, Huang H, Liu Y and Liu J: High expression of Cullin1 indicates poor prognosis for NSCLC patients. Pathol Res Pract. 210:397–401. 2014. View Article : Google Scholar : PubMed/NCBI
43	Lai YJ, Tsai JC, Tseng YT, Wu MS, Liu WS, Lam HI, Yu JH, Nozell SE and Benveniste EN: Small G protein Rac GTPases regulate the maintenance of glioblastoma stem-like cells in vitro and in vivo. Oncotarget. 8:18031–18049. 2017. View Article : Google Scholar : PubMed/NCBI
44	Serra N, Rosales R, Masana L and Vallvé JC: Simvastatin Increases Fibulin-2 expression in human coronary artery smooth muscle cells via RhoA/Rho-kinase signaling pathway inhibition. PLoS One. 10:e01338752015. View Article : Google Scholar : PubMed/NCBI
45	Sizemore ST, Zhang M, Cho JH, Sizemore GM, Hurwitz B, Kaur B, Lehman NL, Ostrowski MC, Robe PA, Miao W, et al: Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell Res. 28:1090–1102. 2018. View Article : Google Scholar : PubMed/NCBI
46	Wang Y, Che S, Cai G, He Y, Chen J and Xu W: Expression and prognostic significance of CTBP2 in human gliomas. Oncol Lett. 12:2429–2434. 2016. View Article : Google Scholar : PubMed/NCBI
47	Dcona MM, Morris BL, Ellis KC and Grossman SR: CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors. Cancer Biol Ther. 18:379–391. 2017. View Article : Google Scholar : PubMed/NCBI
48	Patel J, Baranwal S, Love IM, Patel NJ, Grossman SR and Patel BB: Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells. Cell Cycle. 13:3506–3518. 2014. View Article : Google Scholar : PubMed/NCBI
49	Guo H, Zhang XY, Peng J, Huang Y, Yang Y, Liu Y, Guo XX, Hao Q, An S and Xu TR: RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis. Biochem Biophys Res Commun. 498:932–939. 2018. View Article : Google Scholar : PubMed/NCBI
50	Matias PM, Baek SH, Bandeiras TM, Dutta A, Houry WA, Llorca O and Rosenbaum J: The AAA+ proteins Pontin and Reptin enter adult age: from understanding their basic biology to the identification of selective inhibitors. Front Mol Biosci. 2:172015. View Article : Google Scholar : PubMed/NCBI
51	Mao YQ and Houry WA: The role of pontin and reptin in cellular physiology and cancer etiology. Front Mol Biosci. 4:582017. View Article : Google Scholar : PubMed/NCBI